AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections

by Vandana Singh, Benzinga Editor

April 6, 2021 9:41 AM | 1 min read |

AzurRx BioPharma Inc AZRX has initiated Phase 2 RESERVOIR trial evaluating oral formulation of micronized niclosamide (FW-1022) for the treatment of COVID-19 related gastrointestinal (GI) infections.
Patient enrollment is expected to begin soon, with topline data anticipated in Q1 2022.
The Phase 2 trial is a two-part, two-arm, placebo-controlled study examining the safety and efficacy of FW-1022.
This trial's two primary objectives will be to confirm the safety of niclosamide and demonstrate efficacy in clearing the SARS-CoV-2 virus from the GI tract.
The trial's primary efficacy measure is the rate of fecal SARS-CoV-2 virus clearance (rectal swab or stool sample), comparing the niclosamide arm to the placebo arm for up to six months.
Price Action: AZRX shares are trading 0.95% lower at $0.971 on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Briefs Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.